BlackRock boosts to 7.1% ownership in Amylyx (NASDAQ: AMLX)

Rhea-AI Filing Summary

BlackRock, Inc. has filed an amended Schedule 13G reporting a significant ownership stake in Amylyx Pharmaceuticals, Inc. common stock as of 12/31/2025. BlackRock reports beneficial ownership of 7,783,648 shares, representing 7.1 % of Amylyx’s outstanding common stock.

The filing states that BlackRock has sole power to vote or direct the vote over 7,653,538 shares and sole power to dispose or direct the disposition of 7,783,648 shares, with no shared voting or dispositive power. The securities are described as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 12:30 PM Learn about SEC filing dates

FAQ

How many Amylyx Pharmaceuticals (AMLX) shares does BlackRock beneficially own?

BlackRock, Inc. reports beneficial ownership of 7,783,648 shares of Amylyx Pharmaceuticals, Inc. common stock as of 12/31/2025.

What percentage of Amylyx Pharmaceuticals (AMLX) does BlackRock own?

BlackRock reports that its 7,783,648 beneficially owned shares represent 7.1 % of Amylyx Pharmaceuticals’ outstanding common stock.

How much voting power does BlackRock have in Amylyx Pharmaceuticals (AMLX)?

BlackRock states it has sole power to vote or direct the vote over 7,653,538 shares of Amylyx Pharmaceuticals common stock and no shared voting power.

Does BlackRock share dispositive power over its Amylyx (AMLX) holdings?

No. The filing shows BlackRock has sole dispositive power over 7,783,648 shares and no shared dispositive power for Amylyx Pharmaceuticals common stock.

Is BlackRock’s Amylyx (AMLX) stake intended to influence control of the company?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amylyx Pharmaceuticals.

Who signed the Schedule 13G/A for BlackRock regarding Amylyx (AMLX)?

The statement was signed by Spencer Fleming, Managing Director, on behalf of BlackRock, Inc., with a date of 01/21/2026.

Are any other persons entitled to dividends or sale proceeds from BlackRock’s Amylyx (AMLX) shares?

The filing notes that various persons have rights to receive dividends or sale proceeds from the Amylyx common stock, but no single person’s interest exceeds 5 % of the total outstanding common shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Amylyx Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03237H101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03237H101

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,653,538.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,783,648.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,783,648.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Amylyx Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 43 THORNDIKE STREET CAMBRIDGE MA 02141
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 03237H101
Item 4.	Ownership
(a)	Amount beneficially owned: 7783648
(b)	Percent of class: 7.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 7653538
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 7783648
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Amylyx Pharmaceuticals, Inc.. No one person's interest in the common stock of Amylyx Pharmaceuticals, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	01/21/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7